IL152671A0 - Hcv variants - Google Patents

Hcv variants

Info

Publication number
IL152671A0
IL152671A0 IL15267101A IL15267101A IL152671A0 IL 152671 A0 IL152671 A0 IL 152671A0 IL 15267101 A IL15267101 A IL 15267101A IL 15267101 A IL15267101 A IL 15267101A IL 152671 A0 IL152671 A0 IL 152671A0
Authority
IL
Israel
Prior art keywords
hcv
variants
methods
expression vectors
polynucleotides
Prior art date
Application number
IL15267101A
Other languages
English (en)
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,989 external-priority patent/US7049428B1/en
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL152671A0 publication Critical patent/IL152671A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15267101A 2000-05-23 2001-05-23 Hcv variants IL152671A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/576,989 US7049428B1 (en) 1998-03-04 2000-05-23 HCV variants
PCT/US2001/016822 WO2001089364A2 (en) 2000-05-23 2001-05-23 Hcv variants

Publications (1)

Publication Number Publication Date
IL152671A0 true IL152671A0 (en) 2003-06-24

Family

ID=24306833

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15267101A IL152671A0 (en) 2000-05-23 2001-05-23 Hcv variants
IL152671A IL152671A (en) 2000-05-23 2002-11-06 Polynucleotide comprising a non - naturally occurring hcv sequence that is capable of productive replication in a host cell, vectors, cells and a method for identifying cell line permissive for infection with hcv
IL176731A IL176731A (en) 2000-05-23 2006-07-06 Method for producing a cell line permissive for hcv replication and a cell line produced by said method

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL152671A IL152671A (en) 2000-05-23 2002-11-06 Polynucleotide comprising a non - naturally occurring hcv sequence that is capable of productive replication in a host cell, vectors, cells and a method for identifying cell line permissive for infection with hcv
IL176731A IL176731A (en) 2000-05-23 2006-07-06 Method for producing a cell line permissive for hcv replication and a cell line produced by said method

Country Status (9)

Country Link
EP (1) EP1296998B1 (es)
JP (2) JP4095303B2 (es)
AT (1) ATE525384T1 (es)
AU (1) AU2001263407B9 (es)
CA (1) CA2409873C (es)
DK (1) DK1296998T3 (es)
ES (1) ES2373642T3 (es)
IL (3) IL152671A0 (es)
WO (1) WO2001089364A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
IL156058A0 (en) * 2000-12-22 2003-12-23 Boehringer Ingelheim Ca Ltd Self-replicating rna molecule from hepatitis c virus
EP1423522A2 (en) * 2001-01-23 2004-06-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
DK1490383T3 (da) * 2002-03-11 2009-06-08 Lab 21 Ltd Fremgangsmåde og sammensætning til identifikation og karakterisering af hepatitis C
US7786287B2 (en) * 2002-04-16 2010-08-31 Merck & Co., Inc. Hepatitis C virus assay systems
KR100502864B1 (ko) * 2002-10-09 2005-07-22 (주)팬바이오넷 Ｃ형 간염바이러스의 복제 정량 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 저해제의 탐색방법
CA2505551A1 (en) * 2002-11-13 2004-05-27 Washington University Highly permissive cell lines for hepatitis c virus replication
WO2004074507A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Method to confer cell culture replication activity to different hepatitis c virus isolates
EP2267004A3 (en) * 2003-09-22 2011-04-27 Green Peptide Co., Ltd. Peptide derived from hepatitis C virus
CA2543846C (en) 2003-11-05 2011-04-12 Merck & Co., Inc. Hcv replicons containing ns5b from genotype 2b
EP1783218A4 (en) * 2004-06-25 2009-02-18 Advanced Life Science Inst Inc HCV RNA WITH NEW SEQUENCE
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
JPWO2008136470A1 (ja) * 2007-04-27 2010-07-29 株式会社先端生命科学研究所 Ｈｃｖ遺伝子
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
US20130195914A1 (en) * 2010-04-12 2013-08-01 Viracine Therapeutics Corporation Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof
EP2917340A1 (en) 2012-11-07 2015-09-16 Gilead Sciences, Inc. Hcv genotype 6 replicons
CN112225783B (zh) * 2020-09-16 2021-08-31 东莞市朋志生物科技有限公司 Hcv重组抗原及其突变体

Also Published As

Publication number Publication date
IL176731A0 (en) 2006-10-31
WO2001089364A2 (en) 2001-11-29
WO2001089364A3 (en) 2003-01-23
JP4095303B2 (ja) 2008-06-04
AU6340701A (en) 2001-12-03
AU2001263407B2 (en) 2006-12-07
IL152671A (en) 2009-09-01
JP2003533232A (ja) 2003-11-11
CA2409873A1 (en) 2001-11-29
CA2409873C (en) 2013-01-08
ATE525384T1 (de) 2011-10-15
DK1296998T3 (da) 2011-12-12
JP2007143553A (ja) 2007-06-14
EP1296998A4 (en) 2009-01-28
IL176731A (en) 2009-12-24
ES2373642T3 (es) 2012-02-07
EP1296998A2 (en) 2003-04-02
WO2001089364A9 (en) 2003-07-10
AU2001263407B9 (en) 2007-05-24
EP1296998B1 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
IL176731A0 (en) A method for producing a cell line more permissive for hcv replication and a cell line produced by said method
HK1052468A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype.
ES2020152A4 (es) Diagnosticos y vacunas para nanbv.
PE20020474A1 (es) Compuestos peptidomimeticos como inhibidores de la serina proteasa ns3 del virus de hepatitis c
WO2005030800A3 (en) Oligonucleotide analog and method for treating flavivirus infections
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
CA2437962A1 (en) Method of extracting virus from cell culture
GB9925955D0 (en) Hcv n33 protease inhibitors
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
IL74809A0 (en) Live purified marek's disease vaccine
Monteiro-Vitorello et al. A circular mitochondrial plasmid incites hypovirulence in some strains of Cryphonectria parasitica
GB0009079D0 (en) Herpes viruses for immune modulation
MXPA01005808A (es) Cepa de virus de enfermedad bursal infecciosa para administracion en huevo.
TW200509964A (en) VP1 of foot-and-mouth disease virus
DE60035695D1 (de) Schutzantigen des epstein-barr-virus
Boroń Replication banding patterns in the spined loach, Cobitis taenia L.(Pisces, Cobitidae)
CN212254483U (zh) 一种智能电压力锅性能测试装置
EP0048470A3 (en) Eucaryotically active recombinant dna
TW200610539A (en) A preparation containing alkaline medicament
DE60133102D1 (es)
CA2406853A1 (en) Methods and compositions for eliciting an immune response
CN113734605A (zh) 一种结核分枝杆菌核酸检测试剂盒
Lin et al. Protectivity of the Bivalent Marek's Disease Vaccines in Taiwan Local Chickens
WO2003008556A3 (en) A vector containing an enhanced p15a origin of replication